Compounds > troxacitabine
Page last updated: 2024-09-03

troxacitabine and Thrombopenia

troxacitabine has been researched along with Thrombopenia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW1
Baker, SD; Bélanger, K; Dionne, J; Jolivet, J; Maclean, M; Moore, M; Seymour, L; Siu, L; Soulières, D; Wainman, N1

Trials

2 trial(s) available for troxacitabine and Thrombopenia

ArticleYear
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
    Cancer chemotherapy and pharmacology, 2009, Volume: 65, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Tissue Distribution; Treatment Outcome; Young Adult

2009
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, May-15, Volume: 20, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Dioxolanes; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Thrombocytopenia; Tissue Distribution

2002